InvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for...

InvestmentPitch Media Video Discusses MindBio Therapeutics’ Clinical Trials of LSD-Microdosing Reveals Significant Positive Impact on Quality of Sleep VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, announced a...

InvestmentPitch Media Video Discusses MindBio Therapeutics’ Receipt of Initial Shipment of 1,000,000 Microdoses of LSD for Phase 2 Clinical Trials for Depression VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, received its...

InvestmentPitch Media Video Discusses New CSE Listing MindBio Therapeutics, Pioneering Clinical Studies of Micro-Dosing of Psychedelic Medicines VANCOUVER, British Columbia, May 08, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) is one of the latest new listings on the Canadian Securities Exchange. Based in Melbourne, Australia,...